SGLT2i and GLP-1 agonist therapy for CV risk reduction in patients with DM2
Publication/Presentation Date
1-22-2022
Published In/Presented At
Vengrove, M. (2022, January 22). SGLT2i and GLP-1 agonist therapy for CV risk reduction in patients with DM2. Presented at Lehigh Valley Health Network, Virtual.
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Presentation
COinS
